Overview

Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ

Status:
Completed
Trial end date:
2011-06-30
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen or letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes. PURPOSE: This clinical trial is studying how well tamoxifen or letrozole work in treating women with ductal carcinoma in situ.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
National Cancer Institute (NCI)
Novartis
Treatments:
Letrozole
Tamoxifen